Cargando…

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

BACKGROUND: We assessed the safety, efficacy, and pharmacokinetics of the transforming growth factor beta (TGFβ) receptor inhibitor galunisertib co-administered with the anti-programmed death-ligand 1 (PD-L1) antibody durvalumab in recurrent/refractory metastatic pancreatic cancer previously treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melisi, Davide, Oh, Do-Youn, Hollebecque, Antoine, Calvo, Emiliano, Varghese, Anna, Borazanci, Erkut, Macarulla, Teresa, Merz, Valeria, Zecchetto, Camilla, Zhao, Yumin, Gueorguieva, Ivelina, Man, Michael, Gandhi, Leena, Estrem, Shawn T, Benhadji, Karim A, Lanasa, Mark C, Avsar, Emin, Guba, Susan C, Garcia-Carbonero, Rocio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944986/ https://www.ncbi.nlm.nih.gov/pubmed/33688022 http://dx.doi.org/10.1136/jitc-2020-002068

Ejemplares similares

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer
por: Nadal, Ernest, et al.
Publicado: (2023)

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
por: Herbertz, Stephan, et al.
Publicado: (2015)

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
por: Capper, David, et al.
Publicado: (2017)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
por: Wick, Antje, et al.
Publicado: (2020)

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
por: Rodón, Jordi, et al.
Publicado: (2014)

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
por: Gueorguieva, Ivelina, et al.
Publicado: (2016)

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
por: Giannelli, Gianluigi, et al.
Publicado: (2020)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
por: Giannelli, Gianluigi, et al.
Publicado: (2021)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
por: Siu, Lillian, et al.
Publicado: (2020)

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Kelley, R.K., et al.
Publicado: (2019)

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2023)

Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
por: Jazieh, Khalid, et al.
Publicado: (2022)

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
por: Song, Xuyang, et al.
Publicado: (2023)

Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition
por: Schaer, David, et al.
Publicado: (2015)

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
por: Joshi, Monika, et al.
Publicado: (2023)

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wildsmith, Sophie, et al.
Publicado: (2023)

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
por: Aggarwal, Charu, et al.
Publicado: (2023)

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer
por: Kwon, Minsuk, et al.
Publicado: (2022)

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
por: Hamid, Omid, et al.
Publicado: (2023)

A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
por: Voss, Martin H., et al.
Publicado: (2022)

A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2018)

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
por: Taylor, Kirsty, et al.
Publicado: (2020)

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients
por: Serova, Maria, et al.
Publicado: (2015)

Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes
por: Zhang, Chao, et al.
Publicado: (2016)

Galunisertib enhances chimeric antigen receptor-modified T cell function
por: Wang, Zhixiong, et al.
Publicado: (2020)

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
por: Pakkala, Suchita, et al.
Publicado: (2020)

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
por: Wislez, Marie, et al.
Publicado: (2022)

A rare case of sporadic mismatch repair deficient pancreatic ductal adenocarcinoma that responded to ipilimumab and nivolumab combination treatment: case report
por: Han, Margaret Y., et al.
Publicado: (2023)

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
por: Antill, Yoland, et al.
Publicado: (2021)

Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
por: Johnson, Benny, et al.
Publicado: (2022)

Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer
por: Carbone, Carmine, et al.
Publicado: (2018)

Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
por: Hecht, Markus, et al.
Publicado: (2020)

Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies
por: Han, Margaret Y., et al.
Publicado: (2023)

Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
por: Merz, Valeria, et al.
Publicado: (2020)

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
por: Park, Junsik, et al.
Publicado: (2023)

Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression
por: Rani, Bhavna, et al.
Publicado: (2018)

Galunisertib Exerts Antifibrotic Effects on TGF-β-Induced Fibroproliferative Dermal Fibroblasts
por: Peterson, Joshua M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9gcvu4773u30alq4lce5q70sug